Introduction
Uzbekistan is becoming an increasingly relevant market for pharmaceutical and medical device companies evaluating opportunities across Central Asia. But market entry is not simply a matter of obtaining a registration certificate and beginning commercial activities.
Companies must understand the local regulatory framework, product registration process, certification expectations, post-market obligations, safety reporting requirements, and the way regulatory changes can affect an established product portfolio.
The regulatory environment is also evolving. Uzbekistan’s State Institution “Center for Pharmaceutical Products Safety” under the Ministry of Health oversees important functions covering registration, standardization, certification, technical regulation, and post-marketing control of medicines, medical devices, and medical equipment.
For international manufacturers and marketing authorization holders (MAHs), this makes regulatory planning and pharmacovigilance particularly important. A successful Uzbekistan strategy should connect pre-market regulatory compliance with post-market product safety rather than treating them as separate activities.
Understanding Uzbekistan’s Regulatory Environment
The first step for any pharmaceutical or medical device company entering Uzbekistan is understanding which authority, regulations, procedures, and product-specific requirements apply to the proposed product.
The Center for Pharmaceutical Products Safety maintains the State Register of Medicines and Medical Devices. The register covers domestic and foreign medicines, pharmaceutical substances, in vivo diagnostic products, medical equipment, medical products, and in vitro diagnostic devices.
This distinction is important because requirements can vary depending on:
- Product classification
- Dosage form and route of administration
- Active pharmaceutical ingredient
- Manufacturing location
- Product indication
- Whether the product is a medicine or medical device
- Whether the product is new, already registered, or undergoing a lifecycle change
The regulatory framework should therefore be assessed before compiling the submission dossier.
The regulatory landscape is changing
Uzbekistan’s regulatory environment is continuing to develop. For example, a new procedure for pharmacovigilance of medicinal products and safety monitoring of medical devices was approved through Minister of Health Order No. 18, registered on January 12, 2026. The regulation establishes mechanisms for identifying, assessing, and preventing adverse reactions, lack of efficacy, and medical-device incidents.
For global companies, this demonstrates why regulatory requirements should be monitored continuously rather than treated as static information.
2. What Companies Should Know Before Market Entry
A market-entry strategy should begin with a regulatory gap assessment.
Instead of asking only, “What documents are required?”, regulatory teams should ask:
- Is the product eligible for registration?
- What classification applies?
- What local documentation is required?
- Are translations or specific document formats needed?
- What evidence is expected for quality, safety, and efficacy?
- Are additional certification requirements applicable?
- What post-marketing obligations will apply after approval?
- What local safety-reporting processes must be established?
- How will regulatory changes be monitored throughout the product lifecycle?
This approach can reduce avoidable submission delays and help companies identify regulatory dependencies before they become operational problems.
For companies without an established local regulatory function, Regulatory Affairs Services in Uzbekistan can be considered as part of a broader market-entry support strategy.
The objective should not simply be outsourcing documentation. It should be building a regulatory pathway that remains manageable after the initial approval.
3. Pharmaceutical Registration and Documentation
Registration is one of the most important stages of pharmaceutical market entry.
The Center’s registration department is responsible for issuing registration certificates for domestic and foreign medicinal products, preventive and diagnostic products, medical equipment, and medical products, as well as maintaining information concerning registered products.
According to the Center’s registration FAQ, applicants submit an application together with electronic registration documentation in the prescribed sequence. The FAQ also states a registration review period of 155 days for medicinal products.
However, a regulatory timeline should never be built around a single headline duration.
Actual project planning should also consider:
- Dossier preparation
- Document verification
- Translation and legalization requirements where applicable
- Technical or expert review
- Queries and responses
- Sample or testing requirements where applicable
- Certification activities
- Registration certificate issuance
- Post-approval obligations
Medical device requirements are also evolving
Medical device manufacturers should pay particular attention to recent changes. In January 2026, Uzbekistan approved a procedure for conducting clinical investigations of medical devices. The procedure establishes a framework for assessing safety, effectiveness, and quality, while allowing certain lower-risk or internationally recognized devices to potentially be registered without clinical investigations.
This illustrates a broader point: product classification and regulatory strategy should be established early, before companies commit to a submission pathway.
4. Why Regulatory Intelligence Matters
Regulatory intelligence is becoming increasingly important as pharmaceutical companies manage multiple countries, products, and regulatory changes simultaneously.
A regulatory team may need to track:
- New legislation
- Ministry orders
- Registration procedures
- Safety requirements
- Certification changes
- Submission requirements
- Product-specific guidance
- Regulatory deadlines
- Changes affecting medical devices
- Post-marketing safety obligations
Without a structured monitoring process, teams can discover important changes only when a submission is already being prepared.
This is where Regulatory Intelligence Tools can support a more systematic approach to identifying and organizing regulatory developments.
The important principle is that technology should support regulatory judgment, not replace it. Regulatory professionals still need to assess whether a change is relevant to a particular product, market, indication, or submission strategy.
5. Pharmacovigilance After Product Approval
Regulatory approval is not the end of compliance.
Once a medicinal product is marketed, safety information must continue to be collected, assessed, documented, and communicated appropriately.
The Center for Pharmaceutical Products Safety defines pharmacovigilance as activities involving the detection, assessment, understanding, and prevention of adverse reactions and adverse events associated with medicinal products and medical devices. Its stated objectives include early risk detection, patient safety, and continuous evaluation of benefit-risk balance.
This is consistent with the broader global approach promoted by the World Health Organization (WHO), which emphasizes that some safety problems may only become visible when products are used by larger and more diverse real-world populations after authorization.
For companies operating in Uzbekistan, Pharmacovigilance Services in Uzbekistan can form part of a localized safety-management strategy.
What should a post-market safety system cover?
A practical pharmacovigilance framework may include:
- Adverse event intake
- Case validation
- Seriousness and expectedness assessment
- Medical review
- Coding
- Case follow-up
- Regulatory reporting
- Signal detection
- Aggregate safety evaluation
- Safety communication
- Documentation and quality oversight
The exact operational model should reflect the applicable local requirements and the company’s global safety system.
6. ICSR Processing and Safety Reporting
Individual Case Safety Reports (ICSRs) are a fundamental component of pharmacovigilance.
An ICSR contains information concerning an individual safety case, such as an adverse reaction associated with a medicinal product. Effective processing requires more than simply entering information into a database.
A robust process should ensure that cases are:
- Identified promptly
- Validated against minimum reporting criteria
- Assessed for seriousness
- Medically reviewed where appropriate
- Coded consistently
- Followed up when information is incomplete
- Submitted to the appropriate authority within applicable timelines
- Reconciled with internal safety records
Uzbekistan has also established online mechanisms through which marketing authorization holders, healthcare and pharmaceutical professionals, and members of the public can report adverse reactions.
The country’s 2026 pharmacovigilance framework specifies different reporting periods depending on the type of safety information. For example, the official safety information identifies a one-day period for reactions involving death or life-threatening situations, alongside longer periods for other defined categories.
This makes timely case intake and escalation especially important.
For organizations managing multinational safety operations, ICSR processing and submission Services can support the operational side of case management while the MAH retains appropriate oversight and accountability.
7. Regulatory Lifecycle Management
A product can remain on the market for many years, but its regulatory profile rarely remains unchanged.
Companies may need to manage:
- Manufacturing-site changes
- Manufacturing process changes
- Product information updates
- Safety-related changes
- Labeling changes
- Packaging changes
- Variations
- Renewals
- Regulatory commitments
- New indications
- New safety information
- Product discontinuation
This creates a need for structured lifecycle management.
A centralized approach to regulatory information can help teams connect product data, submissions, changes, deadlines, and regulatory obligations.
For organizations managing complex portfolios, Regulatory Affairs Lifecycle Management tools can help organize lifecycle activities and provide greater visibility across ongoing regulatory work.
The strategic benefit is not simply better record keeping. It is reducing the risk that an important regulatory commitment or change is overlooked as products move through their lifecycle.
8. Practical Market-Entry Checklist
Before entering Uzbekistan, pharmaceutical and medical device companies should consider the following checklist:
- Confirm the applicable product classification.
- Identify the competent regulatory authority and applicable procedures.
- Review current registration requirements.
- Establish a realistic dossier preparation timeline.
- Identify translation, certification, and document-format requirements.
- Assess whether additional testing or clinical evidence may be required.
- Review current certification requirements.
- Establish a local regulatory responsibility model.
- Map post-authorization obligations before approval.
- Establish pharmacovigilance reporting processes.
- Define ICSR intake and escalation procedures.
- Monitor regulatory changes after approval.
- Maintain a lifecycle-management process for variations and renewals.
- Periodically reassess the product’s benefit-risk profile.
- Maintain documented evidence of regulatory and safety activities.
The strongest market-entry strategies integrate these activities from the beginning rather than adding pharmacovigilance and lifecycle compliance after commercialization.
Check our other country services
https://www.ddregpharma.com/global-reach/regulatory-services-in-vietnam
https://www.ddregpharma.com/global-reach/pharmacovigilance-services-in-vietnam
https://www.ddregpharma.com/solutions/pharmacovigilance/literature-monitoring
https://www.ddregpharma.com/solutions/pharmacovigilance/risk-management